ProCE Banner Activity

KEYNOTE-826: Subgroup Analysis of Pembrolizumab + Chemotherapy ± Bevacizumab in Persistent, Recurrent, or Metastatic Cervical Cancer

Slideset Download
Conference Coverage
Pembrolizumab + chemotherapy ± bevacizumab prolonged PFS and OS vs placebo + chemotherapy ± bevacizumab in key patient populations, including those defined by bevacizumab use, histology, platinum use, and prior chemoradiotherapy.

Released: June 09, 2022

Expiration: June 08, 2023

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab